Current:Home > StocksAgreement to cancel medical debt for 193,000 needy patients in Southern states -Streamline Finance
Agreement to cancel medical debt for 193,000 needy patients in Southern states
View
Date:2025-04-11 19:45:47
NEW ORLEANS (AP) — A New Orleans-based system of hospitals and clinics serving Louisiana, Mississippi and Alabama is working with a New York nonprofit to wipe out $366 million in medical debt for about 193,000 needy patients.
The Times-Picayune/The New Orleans Advocate reported Wednesday that the deal involving Ochsner Health was arranged by Undue Medical Debt, a donor-funded organization that negotiates with hospitals, doctors’ offices and ambulance services to purchase and erase the outstanding medical debt of those least able to afford it.
Ochsner is the largest health system in Louisiana and has 46 hospitals and 370 clinics and urgent cares in the three states it serves.
“Ochsner is proud to have worked with Undue Medical Debt to enable the organization to acquire and cancel past one-time debts for eligible residents,” the company said in a statement.
The deal followed a Monday announcement of an agreement between Ochsner, Undue Medical Debt and New Orleans to wipe out more than $59 million in medical debt for about 66,000 patients in that city.
The city had agreed last year to provide Undue Medical Debt with $1.3 million in federal money from the 2021 American Rescue Plan Act, a pandemic program to acquire qualifying debt and erase it.
“The city government gets a lot of credit for getting the ball rolling,” said Daniel Lempert, vice president for communications and marketing at the nonprofit. “Once we got in the door and explained our model to the hospital, there were other debts that qualified for the program.”
Lempert said that in addition to the pandemic dollars, his organization used money it received from donations and grassroots fundraising both locally and nationwide to purchase the debt from Ochsner.
He declined to say how much it paid, but based on what the organization has said it typically pays — about 1 cent for each dollar of debt — the amount would be around $3.6 million.
veryGood! (1287)
Related
- Opinion: Gianni Infantino, FIFA sell souls and 2034 World Cup for Saudi Arabia's billions
- Where Is the Green New Deal Headed in 2020?
- Coronavirus FAQ: Is Paxlovid the best treatment? Is it underused in the U.S.?
- Step Inside Sharon and Ozzy Osbourne's $4.8 Million Los Angeles Home
- Where will Elmo go? HBO moves away from 'Sesame Street'
- Sen. Marco Rubio: Trump's indictment is political in nature, will bring more harm to the country
- Kate Spade 24-Hour Flash Deal: Get This $280 Crossbody Bag for Just $59
- Lindsay Lohan and Jamie Lee Curtis Share Update on Freaky Friday Sequel
- Michigan lawmaker who was arrested in June loses reelection bid in Republican primary
- 90 Day Fiancé: The Other Way Finale Sees Gabe Break Down in Tears During Wedding With Isabel
Ranking
- Person accused of accosting Rep. Nancy Mace at Capitol pleads not guilty to assault charge
- Solar Energy Surging in Italy, Outpacing U.S.
- LeBron James' Wife Savannah Explains Why She's Stayed Away From the Spotlight in Rare Interview
- Mass. Court Bans Electricity Rate Hikes to Fund Gas Pipeline Projects
- Kansas City Chiefs CEO's Daughter Ava Hunt Hospitalized After Falling Down a Mountain
- I usually wake up just ahead of my alarm. What's up with that?
- Shipping Group Leaps Into Europe’s Top 10 Polluters List
- You Didn't See It Coming: Long Celebrity Marriages That Didn't Last
Recommendation
'No Good Deed': Who's the killer in the Netflix comedy? And will there be a Season 2?
New York City mandates $18 minimum wage for food delivery workers
Thousands of dead fish wash up along Texas Gulf Coast
Person of interest named in mass shooting during San Francisco block party that left nine people wounded
Who's hosting 'Saturday Night Live' tonight? Musical guest, how to watch Dec. 14 episode
You can order free COVID tests again by mail
Coronavirus FAQ: Is Paxlovid the best treatment? Is it underused in the U.S.?
CRISPR gene-editing may boost cancer immunotherapy, new study finds